At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 215 enrolled
Drug / intervention
Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis
In Brief
A Phase 4 clinical trial evaluating Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®) for Allergic Conjunctivitis. Completed, enrolled 215 participants.
Detailed Summary
The purpose of this study is to evaluate patient perceptions of olopatadine 0.2% dosed once daily in patients previously treated with twice-daily, topical, ocular, anti-allergy medications.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2010
First PostedJul 2010
Primary CompletionAug 2010
TodayJul 2026
First PostedJul 9, 2010
Enrollment StartJun 1, 2010
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 16.0 years ago
Interventions
Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)drug
Commercially marketed ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis